{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Clinical benefit response rate (sCR/CR/VGPR/partial response \\[PR\\]/minimal response \\[MR\\] or stable disease \\[SD\\]), assessed by International Myeloma Working Group (IMWG) criteria","groups":[{"description":"Patients receive 20 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm 1: 20 mg Leflunomide"},{"description":"Patients receive 40 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm 2: 40 mg Leflunomide"},{"description":"Patients receive 60 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Arm 3: 60 mg Leflunomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable patients. One patient was non-compliant, therefore, inevaluable. Because we obtained preclinical data indicating a synergistic effect between leflunomide and lenalidomide, we determined that investigating leflunomide-based combinational therapy was favorable over pursuing a phase 2 study of single-agent leflunomide. There were no dose de-escalations, so there were no patients accrued to the arms for 10mg, 30mg, or 50mg.","reportingStatus":"POSTED","timeFrame":"From the start of treatment until disease progression/recurrence, assessed up to 48 months","title":"Clinical Benefit Response Rate (sCR/CR/VGPR/Partial Response [PR]/Minimal Response [MR] or Stable Disease [SD]), Assessed by IMWG Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}